3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
1
Phase 1/2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Biliary Tract Neoplasms
2
Stomach Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Metastatic HER2-positive Breast Cancer
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Cholangiocarcinoma
1
Advanced Malignancies
1
Adenocarcinoma Of Esophagus
1
Interventions
Oxaliplatin
56
Capecitabine
49
Fluorouracil
37
Cisplatin
37
S 1 (combination)
23
Paclitaxel
18
Docetaxel
18
Leucovorin
16
pembrolizumab
13
Irinotecan
12
apatinib
11
titanium silicide
9
XELOX
9
Trastuzumab
9
Nivolumab
9
Hyperthermic Intraperitoneal Chemotherapy
8
Epirubicin
8
Drug Therapy
8
Tegafur
7
Radiotherapy
6
Neoadjuvant Therapy
6
gimeracil
5
Surgical Procedures, Operative
5
Gastrectomy
5
Chemotherapy, Adjuvant
5
tislelizumab
4
S-1 plus cisplatin
4
Ramucirumab
4
zolbetuximab
3
sintilimab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Stomach Neoplasms
×
zanidatamab
×
Clear all
NCT05152147
2026-05-19
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3
Active not recruiting
920 enrolled